Cart
sales@molnova.com
Nothofagin
CAS No. 11023-94-2
Nothofagin( —— )
Catalog No. M37740 CAS No. 11023-94-2
Nothofagin has antioxidant, and antithrombotic activities, it possesses anti-inflammatory activity by inhibiting hyperpermeability, expression of CAMs, and adhesion and migration of leukocytes, thereby endorsing its usefulness as a therapy for vascular inflammatory diseases.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 701 | In Stock |
|
| 5MG | 620 | In Stock |
|
| 10MG | 844 | In Stock |
|
| 25MG | 1264 | In Stock |
|
| 50MG | 1628 | In Stock |
|
| 100MG | 2213 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameNothofagin
-
NoteResearch use only, not for human use.
-
Brief DescriptionNothofagin has antioxidant, and antithrombotic activities, it possesses anti-inflammatory activity by inhibiting hyperpermeability, expression of CAMs, and adhesion and migration of leukocytes, thereby endorsing its usefulness as a therapy for vascular inflammatory diseases.
-
DescriptionNothofagin, a dihydrochalcone, is isolated from rooibos (Aspalathus linearis). Nothofagin downregulates NF-κB translocation through blocking calcium influx. Nothofagin has antioxidant activity and ameliorates various inflammatory responses such as the septic response and vascular inflammation.
-
In VitroNothofagin pre-treatment (0.1, 1, 10 μM) decreases the level of histamine release in RBL-2H3 and RPMCs cells. The production of cytokines are downregulated bynothofagin pre-treatment Nothofagin (TNF-α: 1-10 μM; IL-4: 0.1-10 μM, IL-6: 1-10 μM).Pre-treatment of DNPHSA-stimulated RBL-2H3 with Nothofagin (10 μM) markedly suppresses the phosphorylation of Lyn, Syk, and Akt.Nothofagin (30 μM; for 6 hours) results in inhibited formation of LPS-induced (100 ng/mL; 4 hours) paracellular gaps with the formation of dense F-actin rings in HUVECs. Nothofagin suppresses IgE-mediated mast cell degranulation both in vitro and in vivo.
-
In VivoNothofagin (1 mg/kg; orally; once a day; for 7 days) significantly increases the urinary volume of both normotensive (NTR) and spontaneously hypertensive rats (SHR).Animal Model:Male Wistar normotensive and spontaneously hypertensive rats (3-4 months old) Dosage:1 mg/kg Administration:Orally; once a day; for 7 days Result:Significantly increased the urinary volume of both NTR and SHR.
-
Synonyms——
-
PathwayApoptosis
-
TargetIL Receptor
-
RecptorIL Receptor | ERK | TNF
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number11023-94-2
-
Formula Weight436.41
-
Molecular FormulaC21H24O10
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESOC1=C(C(O)=CC(O)=C1C(CCC2=CC=C(O)C=C2)=O)[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Wonhwa Lee, et al. Anti-inflammatory Effects of Aspalathin and Nothofagin From Rooibos (Aspalathus Linearis) In Vitro and In Vivo. Inflammation. 2015 Aug;38(4):1502-16.?
molnova catalog
related products
-
Tildrakizumab
Tildrakizumab (SCH 900222) is a potent humanized monoclonal antibody targeting the p19 subunit of IL-23 with a Kd value of 136 pM, useful for studying psoriasis.
-
Enokizumab
Enokizumab?(MEDI-528) is a monoclonal antibody against interleukin IL-9. Enokizumab can be used to study asthma.
-
NFAT inhibitor, Cell...
NFAT inhibitor. Inhibits LPS or LPS plus IFN-γ-induced IL-12 p40, IL-12 p70, IL-23 and TNF secretion from bone marrow-derived macrophages (BMDMs). Also attenuates NO production and Nos2 mRNA expression in LPS-stimulated BMDMs. Improves symptoms in a mouse model of colitis. Exhibits immunosuppressive effects; enhances graft survival in mice. Cell permeable.
